These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
122 related items for PubMed ID: 20649629
1. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Diabetes Obes Metab; 2010 Sep; 12(9):772-9. PubMed ID: 20649629 [Abstract] [Full Text] [Related]
2. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V. Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605 [Abstract] [Full Text] [Related]
3. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. Dailey G, Strange P. Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742 [Abstract] [Full Text] [Related]
4. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M. Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604 [Abstract] [Full Text] [Related]
5. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis. Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA. Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233 [Abstract] [Full Text] [Related]
6. Insulin glargine for type 2 diabetes. Hemraj F, Garces K. Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441 [Abstract] [Full Text] [Related]
7. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Rhoads GG, Kosiborod M, Nesto RW, Fonseca VA, Lu SE, Zhang Q, Foody JM. Am J Cardiol; 2009 Oct 01; 104(7):910-6. PubMed ID: 19766755 [Abstract] [Full Text] [Related]
8. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Monami M, Marchionni N, Mannucci E. Diabetes Res Clin Pract; 2008 Aug 01; 81(2):184-9. PubMed ID: 18495286 [Abstract] [Full Text] [Related]
9. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)]. Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T. Dtsch Med Wochenschr; 2009 Jun 01; 134(23):1207-13. PubMed ID: 19472091 [Abstract] [Full Text] [Related]
10. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Peterson GE. Curr Med Res Opin; 2006 Dec 01; 22(12):2613-9. PubMed ID: 17166343 [Abstract] [Full Text] [Related]
11. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, Kalra S. Curr Med Res Opin; 2009 Dec 01; 25(12):2887-94. PubMed ID: 19821654 [Abstract] [Full Text] [Related]
12. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M. Diabetes Res Clin Pract; 2006 Jul 01; 73(1):35-40. PubMed ID: 16513202 [Abstract] [Full Text] [Related]
13. Basal insulins: Pharmacological properties and patient perspectives. Abrahamson MJ. Prim Care Diabetes; 2010 Apr 01; 4 Suppl 1():S19-23. PubMed ID: 20394887 [Abstract] [Full Text] [Related]
14. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Davis MD, Beck RW, Home PD, Sandow J, Ferris FL. Exp Clin Endocrinol Diabetes; 2007 Apr 01; 115(4):240-3. PubMed ID: 17479440 [Abstract] [Full Text] [Related]
15. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Karges B, Boehm BO, Karges W. Diabet Med; 2005 Oct 01; 22(10):1444-5. PubMed ID: 16176210 [Abstract] [Full Text] [Related]
16. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. Hermansen K, Dornhorst A, Sreenan S. Curr Med Res Opin; 2009 Nov 01; 25(11):2601-8. PubMed ID: 19739940 [Abstract] [Full Text] [Related]
17. Insulin glargine: a long-acting insulin for diabetes mellitus. Garces K. Issues Emerg Health Technol; 2003 Nov 01; (52):1-4. PubMed ID: 14626260 [Abstract] [Full Text] [Related]
18. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens. Mathur SK, Bansal A, Khan ZY. J Indian Med Assoc; 2009 Nov 01; 107(11):759-61. PubMed ID: 20469779 [Abstract] [Full Text] [Related]
19. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Yki-Järvinen H. Eur J Clin Invest; 2004 Jun 01; 34(6):410-6. PubMed ID: 15200492 [Abstract] [Full Text] [Related]
20. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ. Curr Med Res Opin; 2005 Feb 01; 21(2):291-8. PubMed ID: 15802000 [Abstract] [Full Text] [Related] Page: [Next] [New Search]